wasif n khan

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (69)

• Role of animal models in understanding the mechanisms of autoimmune diseases.
  Autoimmunity 2025 DOI: 10.1080/08916934.2025.2531766
  +Save
• BTK drives neutrophil activation for sterilizing antifungal immunity.
  The Journal of clinical investigation 2024 DOI: 10.1172/jci176142
  +Save
• Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
  2023 DOI: 10.1158/1535-7163.c.6538365.v1
  +Save
• Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
  2023 DOI: 10.1158/1535-7163.c.6538365
  +Save
• Supplementary Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
  2023 DOI: 10.1158/1535-7163.22506318.v1
  +Save
• Supplementary Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
  2023 DOI: 10.1158/1535-7163.22506318
  +Save
• Btk Supports Autoreactive B Cell Development and Protects against Apoptosis but Is Expendable for Antigen Presentation
  The Journal of Immunology 2021 DOI: 10.4049/jimmunol.2000558
  +Save
• Impaired B Cell Apoptosis Results in Autoimmunity That Is Alleviated by Ablation of Btk.
  Frontiers in immunology 2021 DOI: 10.3389/fimmu.2021.705307
  +Save
• Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
  Molecular Cancer Therapeutics 2020 DOI: 10.1158/1535-7163.MCT-19-0135
  +Save
• Editorial overview: B cell shades of diversity and memory.
  Current opinion in immunology 2019 DOI: 10.1016/j.coi.2019.04.006
  +Save